Sign in
4

Changes in Ownership

IRulya Therapeutics Inc. Filed Acc 0001209191-23-006394

Options or other derivatives

  • Chief Business Officer acquired 225,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hannah Brendan Chief Business Officer 2023-02-01 Grant or award · Employee Stock Option (right to buy) +225,000 225,000 D: show line 1 in the form
Loading xslF345X03/doc4.xml…